Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CELEBREX

« Back to Dashboard
Celebrex is a drug marketed by Gd Searle and is included in one NDA. It is available from twenty-six suppliers.

The generic ingredient in CELEBREX is celecoxib. There are twenty-two drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

Summary for Tradename: CELEBREX

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list211
2013 Sales:$2,237,658,000

Pharmacology for Tradename: CELEBREX

Clinical Trials for: CELEBREX

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
Status: Completed Condition: Lung Cancer

The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
Status: Completed Condition: Ovulation; Luteal Development

Celecoxib for Pediatric Adenotonsillectomy
Status: Completed Condition: Tonsillectomy; Adenotonsillectomy; Pain, Postoperative

Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
Status: Active, not recruiting Condition: Knee Osteoarthritis

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Status: Completed Condition: Recurrent Respiratory Papillomatosis

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B
Status: Active, not recruiting Condition: Healthy

Celecoxib as a Chemopreventive Agent in Current and Former Smokers
Status: Completed Condition: Smoking; Prevention

The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children
Status: Not yet recruiting Condition: Pharmacokinetics of Celecoxib in Children

Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
Status: Completed Condition: Breast Neoplasms; Breast Cancer

European Celecoxib Trial in Primary Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-004Dec 15, 2006RXNo<disabled><disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-003Aug 29, 2002RXYes<disabled><disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-001Dec 31, 1998RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CELEBREX

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-004Dec 15, 20065,466,823*PED<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-001Dec 31, 1998RE44048*PED<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-003Aug 29, 2002RE44048*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CELEBREX

Drugname Dosage Strength RLD Submissiondate
celecoxibCapsules50 mgCelebrex3/21/2008
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc